Pan-cancer analysis reveals unique molecular patterns associated with age

- 2
- 3 Yajas Shah^{1,2,3,#}, Akanksha Verma^{1,2,4,#}, Andrew Marderstein^{1,2,4}, Bhavneet Bhinder^{1,2}, Olivier
- 4 Elemento^{1,2,3,4,*}
- 5
- 6 ¹Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New
- 7 York, NY 10021, USA
- 8 ² Institute of Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA
- 9 ³ Physiology, Biophysics and Systems Biology Graduate Program, Weill Cornell Medicine, New
- 10 York, NY 10065, USA
- ⁴ Tri-Institutional Program in Computational Biology and Medicine, Weill Cornell Medicine,
- 12 New York, NY 10065, USA
- 13
- 14 [#] These authors contributed equally
- 15 * Correspondence: <u>ole2001@med.cornell.edu</u>

Pan-cancer analysis reveals unique molecular patterns associated with age

16 Abstract

Older age is a strong risk factor for several diseases, including cancer. In cancer, older 17 18 age is also frequently associated with a more aggressive, treatment-refractory tumor phenotype. 19 The etiology and biology of age-associated differences among cancers are poorly understood. To address this knowledge gap, we sought to delineate the differences in tumor molecular 20 21 characteristics between younger and older patients across a variety of tumor types. We found that 22 tumors in younger and older patients exhibit widespread molecular differences. First, we 23 observed that tumors in younger individuals, unlike those in older ones, exhibit an accelerated 24 molecular aging phenotype associated with some hallmarks of premature senescence. Second, 25 we found that tumors from younger individuals are enriched for driver gene mutations resulting in homologous recombination defects. Third, we observed a trend towards a decrease in immune 26 infiltration and function in older patients and found that, immunologically, young tumor tissue 27 28 resembles aged healthy tissue. Taken together, we find that tumors from young individuals 29 possess unique characteristics compared to tumors in older individuals, which can potentially be 30 leveraged for differential therapeutic strategies.

Pan-cancer analysis reveals unique molecular patterns associated with age

31 Introduction

32	Aging refers to the decline in physiological functions with time, resulting in an increased
33	risk of disease. Although advances in healthcare have extended lifespan substantially, cancer
34	continues to be a significant contributor to global mortality. The United States projects 1.8
35	million new cancer cases and 600,000 cancer-related deaths in 2020(Siegel et al., 2020). Several
36	diseases, including cancer, are typically diagnosed in older populations. Older patients frequently
37	have worse outcomes. The molecular correlates of such age-associated differences are not
38	known.
39	Moreover, the incidence of cancer in young adults is increasing at an alarming rate
40	(Ahnen et al., 2014; Anders et al., 2009; Ben-Aharon et al., 2019). In the United States, one in
41	twenty-nine males and one in seventeen females under the age of 49 are likely to develop cancer
42	as per a recent report(Siegel et al., 2020). Tumors in the breast, colon, rectum, genital tract, skin,
43	connective tissue, and thyroid gland are the most common in this age group (Bleyer et al., 2008;
44	Jemal et al., 2010; Siegel et al., 2020).
45	It is unclear whether tumors in younger and older adults have distinct biology. Breast
46	cancers in young adults are typically larger, often harbor the triple-negative phenotype, and are
47	associated with mutations in BRCA1, BRCA2, and TP53 (Anders et al., 2009; Lalloo et al.,
48	2006). Colorectal cancers in young adults may have a high degree of microsatellite instability
49	(MSI) and are enriched for mutations in MYCBP2, BRCA2, PHLPP1, TOPORS, and ATR
50	compared to older patients(Tricoli et al., 2018). While several lines of evidence suggest that
51	cancers in young adults show unique histology and survival heterogeneity, their biology has not
52	been well characterized (Bleyer et al., 2008; Keegan et al., 2016).

- 53 In this study, we conduct an unbiased analysis of primary tumors in The Cancer Genome
- 54 Atlas (TCGA) to understand the biology of cancers in younger vs. older individuals.
- 55 Furthermore, we sought to elucidate genomic, epigenomic, and transcriptomic aberrations in
- 56 younger and older patients and contrast them with healthy tissue. Understanding the unique
- 57 biology of tumors in younger and older patients may lead to personalized therapeutic strategies
- 58 and the development of additional biomarkers.

Pan-cancer analysis reveals unique molecular patterns associated with age

59 **Results**

60 Identification of age-associated cancers

61 We first sought to identify cancers with significant age-dependent outcomes in TCGA, reasoning that the biology underlying the difference in outcomes may be more acute and 62 63 interpretable in such cancers compared to cancers with no age-associated outcome differences. 64 These cancer types were identified by a two-step filtration process involving a Cox-proportional hazards model as well as differential gene expression of primary tumors. First, tumor types in 65 66 which the overall survival (OS) of a patient stratified by age at diagnosis were selected by Cox regression using age at diagnosis as a covariate. This identified thyroid carcinoma (THCA), low-67 68 grade gliomas (LGG), acute myeloid leukemia (LAML), uterine corpus endometrial carcinoma (UCEC), glioblastoma multiforme (GBM), breast invasive carcinoma (BRCA), bladder 69 urothelial carcinoma (BLCA), colon adenocarcinoma (COAD), kidney renal cell carcinoma 70 71 (KIRC), skin cutaneous melanoma (SKCM), ovarian carcinoma (OV) and head and neck squamous cell carcinoma (HNSC) as tumor types in which overall survival was inversely related 72 73 to age (FDR < 0.01, Fig. 1A, Supplementary Table 1). We divided samples from each of these tumor types into quartiles based on their age of diagnosis. The first and fourth quartile served as 74 vounger and older age groups, respectively (Supplementary Fig. 1A, Supplementary Table 2). 75 76 Next, we identified tumors with an age-dependent molecular phenotype by differential gene 77 expression (DGE) of younger and older groups. Tumor types that had greater than 1% of genes 78 differentially expressed between the age groups were deemed to show an age-associated 79 molecular phenotype (FDR < 0.05, Fig. 1B) and were selected for all further analyses. Tumor 80 types in this group included BRCA, LGG, UCEC, OV, THCA, and COAD.

Pan-cancer analysis reveals unique molecular patterns associated with age

81	We wondered whether younger age groups would be associated with early-stage tumors.
82	To our surprise, we did not find any association between age groups and tumor stage in most
83	tumor types of interest; THCA was the only tumor type that displayed this trend. In THCA,
84	Stage I tumors were associated with younger patients, while higher stages were associated with
85	older patients (FDR < 0.05, Supplementary Fig. 1B).
86	

87 Aging drives proliferation and immune dysfunction in cancer

88 We sought to explore the association between age and functional aspects of tumor 89 progression. To do this, we correlated gene expression levels of commonly used tumor progression markers (MYBL2, TOP2A, PLK1, CCND1, PCNA, and MKI67) with patient age. We 90 91 found that in most tumor types, higher gene expression levels of these markers were inversely 92 correlated with age, that is, more highly expressed in younger patients, indicating that tumors from younger patients may be more aggressive than those in older ones (FDR < 0.05, 93 Supplementary Fig. 1C). To further explore this, we sought out to obtain a more detailed 94 95 understanding of transcriptional changes associated with aging in cancer using differential gene 96 expression. Of the tumor types we analyzed, we found that the BRCA, LGG, and UCEC had the 97 most differentially expressed genes between younger and older patients (Fig. 1B). In line with the greater expression of proliferation markers in young patients, we found that gene set 98 99 enrichment analysis of young vs. old DGE results for KEGG pathways associated with tumor 100 growth linked younger patients to a proliferative phenotype (FDR < 0.05, Supplementary Fig. 101 1D).

102 Overall, we found that genes differentially expressed with aging show a high degree of103 overlap across tumor types, suggesting that at least some of the biology underlying aging

104	processes in cancer is consistent across tissue types. Using pairwise Fisher's exact tests, we
105	found that there is a greater overlap between overexpressed genes in younger patients across
106	tumor types as compared to older ones (FDR < 0.05 , Supplemental Fig. 1E). Seventeen genes
107	were over-expressed in younger cohorts across more than three tumor types. These genes
108	included ZNF518B, EDNRA, GMEB1, PPP1R10, and FERMT1 and have been linked to tumor
109	growth, metastasis and poor survival in a variety of cancers(An et al., 2019; Gimeno-Valiente et
110	al., 2019; Kavela et al., 2013; Laurberg et al., 2014; Liu et al., 2017). In contrast, we found ten
111	genes to be over-expressed in old patients across at least three out of six tumor types. These
112	include COQ3, EYA4, FER1L5, HOXB5, SYS1 and TSNAX and have been associated with a
113	variety of cellular functions including mitochondrial function, tumorigenesis, memory formation
114	and protein trafficking(Behnia et al., 2004; Cannon et al., 2005; Jonassen and Clarke, 2000; Lee
115	et al., 2018). Altogether these findings indicate that primary tumors in younger patients have
116	increased expression of tumor proliferation, progression, and metastasis genes. We hypothesized
117	that such tumors while having better outcomes than in older patients, are, in fact, more
118	aggressive but perhaps restrained by a more functional immune system.
119	To explore this hypothesis, we conducted gene set enrichment analyses of differential
120	expression results. This analysis showed that younger patients were enriched for pathways
121	associated with immune response in BRCA, THCA, OV, and UCEC cohorts (FDR < 0.05 , Fig.
122	2A). Interestingly, we found that older patients in the LGG and COAD cohorts displayed the
123	opposite pattern and were enriched for immune-associated pathways compared to younger
124	patients, suggesting that aging-associated effects were tumor type specific. It is possible that this
125	enrichment was associated with inflammaging rather than anti-tumor immunity. Inflammaging
126	refers to inflammation commonly associated with aging and is considered to be one of the

Pan-cancer analysis reveals unique molecular patterns associated with age

several evolutionarily conserved pillars of senescence (Franceschi et al., 2018; Montecino-

128 Rodriguez et al., 2013; Nikolich-Žugich, 2018).

129 Next, we aimed to understand whether the previously mentioned transcriptional changes 130 reflected aging specific to cancer or were simply a consequence of healthy aging. To address this question, we compared young vs. old differential gene expression results from TCGA with the 131 132 results from an identical analysis performed on healthy tissue (sourced from the Genotype-Tissue Expression project (GTEx) project). This analysis allowed us to identify tissue-type specific 133 134 genes associated with aging (Supplementary Fig. 1F). EYA4, a gene associated with hearing 135 loss and cardiomyopathy(Abe et al., 2018), was over-expressed in older individuals regardless of 136 cancer status in four out of six tissue types. Similarly, HENMT1, NOA1, and ZNF518B were over-expressed in younger individuals in three out of six tissue types. These genes have been 137 138 linked to piRNA methylation(Begik et al., 2020), mitochondrial function(Kolanczyk et al., 139 2011), and tumorigenesis(Gimeno-Valiente et al., 2019). 140 We included the METABRIC dataset (breast cancer) and further investigated these 141 results at the level of activated pathways using GSEA. This analysis showed that the relationship 142 between aging in cancer and healthy aging was tumor type-dependent (Fig. 2B). We found that in breast cancer, immune pathways (allograft rejection, IL-2 signaling, inflammatory response, 143 144 interferon a/y response, complement, IL-6 signaling, apoptosis, and TNFa signaling) were 145 overall upregulated in older healthy donors and, as shown above, in young cancer patients (FDR 146 < 0.05, Fig. 2B). While thyroid cancer showed a similar phenotype of pathway activation, other 147 tumor types did not display this pattern. Thus, patterns of pathway activation suggest that 148 younger breast and thyroid cancer patients resemble immunological phenotypes of aged 149 corresponding healthy tissue, indicating dysregulation of the aging process in cancer (Fig. 2B).

150	To obtain a more granular understanding of immune function, we correlated immune cell
151	infiltration (estimated using CIBERSORT(Newman et al., 2015)) with age tumor diagnosis. We
152	found that the correlation between age and specific cell types varied between tumor types (Fig.
153	2C). While we did not observe any strong correlations involving specific cell populations, we
154	found that immune cells with anti-tumor potential were predominantly associated with younger
155	populations. Indeed we found that CD8 ⁺ T cells were associated with younger THCA and UCEC
156	patients. Similarly, CD4 ⁺ resting memory T cells were associated with younger BRCA and OV
157	patients. M1 macrophages and antibody-secreting plasma cells were linked to younger BRCA
158	patients (FDR < 0.05). Interestingly, older BRCA patients showed an increase in M2
159	macrophages, and LGG patients were associated with $CD8^+$ T cells (FDR< 0.05). Memory B
160	cells were associated with older patients in BRCA and UCEC (FDR < 0.05). While the role of B
161	cells in cancer is tumor-type dependent and remains controversial(Garaud et al., 2019; Zhang et
162	al., 2016), M2 macrophages are one of the major immunosuppressive species in the tumor
163	microenvironment(Pyonteck et al., 2013). However, increased T cell infiltration has been
164	unequivocally shown to result in a more robust anti-tumor response and better prognosis in
165	multiple tumor types(Hodi et al., 2010; Le et al., 2015; Topalian et al., 2012). These data are
166	concordant with increased enrichment of immune infiltrating cells in young patients.
167	Taken together, we observed that several genes associated with progression, metastasis,
168	and poor survival outcomes are associated with primary tumors from younger patients.
169	Furthermore, we show that while immune pathway enrichment with aging occurs in a tumor-type
170	specific manner, younger patients typically may harbor a more robust immune response in the
171	tumor microenvironment. This appears to balance the effect of aggressive gene expression
172	profiles (Supplementary Fig. 1D) found in these patients.

Pan-cancer analysis reveals unique molecular patterns associated with age

173

174 Functional analysis of age-associated DNA methylation marks

Most mammalian cells undergo global loss of DNA methylation marks and other epigenetic modifications with aging, which consequently result in transcriptional imbalances(Sen et al., 2016). We hypothesized that a methylation signature of aging would exist in tumors as well. To test this, we identified tumor type-specific differentially methylated genes for the age groups of interest (see Methods). We found that LGG and BRCA had the highest number of differentially methylated genes (**Supplemental Fig. 1G**). Interestingly, a high percentage of genes were hypermethylated in older patients from the COAD, THCA, and BRCA cohorts

182 (Supplemental Fig. 1G).

183 As expected, we found a robust association between hypomethylated and over-expressed 184 genes (Fig. 2D). This association was strongest in genes over-expressed in younger patients, 185 where all tumor types showed significant overlaps with hypomethylated genes (FDR < 0.05, Fig. 186 2D). In contrast, there were fewer overlaps between DNA hypomethylation and gene expression 187 of genes that were over-expressed in older populations, where only OV showed this trend. 188 We created gene lists representing the age-stratified (young or old) tumor-type specific 189 intersection of hypomethylated and over-expressed genes. Next, we conducted Reactome 190 pathway enrichment analysis(Yu and He, 2016) of these gene sets to understand epigenetically 191 driven alterations. We found that gene lists from old LGG, THCA, and UCEC patients were 192 enriched for few pathways (phases in mitosis, mTORC signaling, glycosylation), while the gene 193 list from younger BRCA patients, but not older BRCA patients, was enriched for multiple 194 pathways (Supplementary Table 3). Several pathways associated with the gene list obtained from 195 young breast cancer patients were linked to senescence (senescence associated secretory

196	phenotype, cellular senescence, oxidative-stress induced senescence), epigenomic
197	reprogramming (HDACs deacetylate histones, HDMs demethylate histones, DNA methylation),
198	oncogenic signaling (Wnt signaling), and DNA damage response (DNA double-strand break
199	response) (Fig. 2E). These features describe aging imbalance and oncogenic processes, which
200	may, in part, explain the aggressiveness of tumors from younger breast cancer patients.
201	Taken together, we show that genes that are over-expressed in younger cancer patients
202	may be epigenetically controlled. Furthermore, epigenetically controlled pathways associated
203	with young breast cancer patients, but not other cancers, are enriched for senescence, suggesting
204	dysregulated aging in the tumor.
205	
206	Tumors from young patients exhibit accelerated molecular aging and are senescent
207	To understand the extent of aging-imbalance, we characterized the molecular age of a
208	tumor in terms of the gene expression and DNA methylation (DNAm) profiles. We estimated the
	tunior in terms of the gene expression and DIVA methylation (DIVAII) promes. We estimated the
209	DNAm age from BRCA, LGG, UCEC, THCA, and COAD TCGA cohorts (Supplementary
209 210	
	DNAm age from BRCA, LGG, UCEC, THCA, and COAD TCGA cohorts (Supplementary
210	DNAm age from BRCA, LGG, UCEC, THCA, and COAD TCGA cohorts (Supplementary Table 4) and found a weak correlation with chronological age ($R = 0.12$, $p = 6.6 \times 10^{-8}$) in primary
210 211	DNAm age from BRCA, LGG, UCEC, THCA, and COAD TCGA cohorts (Supplementary Table 4) and found a weak correlation with chronological age ($R = 0.12$, $p = 6.6 \times 10^{-8}$) in primary tumor samples (Fig. 3A). We did not estimate the DNAm age of the OV cohort since there were
210 211 212	DNAm age from BRCA, LGG, UCEC, THCA, and COAD TCGA cohorts (Supplementary Table 4) and found a weak correlation with chronological age ($R = 0.12$, $p = 6.6x10^{-8}$) in primary tumor samples (Fig. 3A). We did not estimate the DNAm age of the OV cohort since there were not enough samples for statistical analysis. Interestingly, the DNAm age of healthy normal
210 211 212 213	DNAm age from BRCA, LGG, UCEC, THCA, and COAD TCGA cohorts (Supplementary Table 4) and found a weak correlation with chronological age ($R = 0.12$, $p = 6.6 \times 10^{-8}$) in primary tumor samples (Fig. 3A). We did not estimate the DNAm age of the OV cohort since there were not enough samples for statistical analysis. Interestingly, the DNAm age of healthy normal adjacent tissue from TCGA (NAT) showed a high correlation with actual patient age ($R = 0.79$, p
210 211 212 213 214	DNAm age from BRCA, LGG, UCEC, THCA, and COAD TCGA cohorts (Supplementary Table 4) and found a weak correlation with chronological age ($R = 0.12$, $p = 6.6x10^{-8}$) in primary tumor samples (Fig. 3A). We did not estimate the DNAm age of the OV cohort since there were not enough samples for statistical analysis. Interestingly, the DNAm age of healthy normal adjacent tissue from TCGA (NAT) showed a high correlation with actual patient age ($R = 0.79$, p $< 2.2x10^{-16}$), suggesting that aberrant epigenetic landscape of the tumor alters its epigenetic age.
210 211 212 213 214 215	DNAm age from BRCA, LGG, UCEC, THCA, and COAD TCGA cohorts (Supplementary Table 4) and found a weak correlation with chronological age ($R = 0.12$, $p = 6.6x10^{-8}$) in primary tumor samples (Fig. 3A). We did not estimate the DNAm age of the OV cohort since there were not enough samples for statistical analysis. Interestingly, the DNAm age of healthy normal adjacent tissue from TCGA (NAT) showed a high correlation with actual patient age ($R = 0.79$, p $< 2.2x10^{-16}$), suggesting that aberrant epigenetic landscape of the tumor alters its epigenetic age. By comparing the donor age with DNAm age, we found that tumors from young and middle-

219	observed in younger populations. These results are in line with previous work, which showed
220	that very young breast cancer patients had accelerated epigenetic ages(Oltra et al., 2019). Indeed,
221	consistent with the findings of Horvath, 2013, apart from LGG, most tumor types tested
222	exhibited the trend of reduced age acceleration upon aging (Fig. 3C).
223	After observing this phenotype in DNA methylation, we aimed to recapitulate these
224	findings in gene expression data. In order to do so, we used the framework set up by Ren and
225	Kuan, 2020. Similar to the DNAm age calculator, Ren & Kuan have trained tissue-type specific
226	age predictors for RNA-Seq data. We imputed RNA age using these tissue-specific models for
227	BRCA, COAD, THCA, and UCEC (Supplementary Table 5). The analysis was limited to these
228	tumor types because Ren & Kuan do not provide regression coefficients for other tissue types, or
229	because there were no healthy samples in our dataset. Similar to the DNAm age calculator, the
230	RNA age for healthy tissue correlated with chronological age much better than tumor tissue
231	(Supplementary Fig. 2). Interestingly, we observed a similar trend of reduced age acceleration
232	upon aging ($p < 0.05$, Fig. 3D). While we did not observe accelerated aging in tumors from
233	young patients (potentially due to sample size), tumors from old patients had reduced age
234	acceleration when compared with matched healthy tissue ($p < 0.05$, Fig. 3E).
235	Next, we sought to further examine accelerated aging at the transcriptional level in breast
236	cancer using gene signatures of aging. We focused this analysis on breast cancer since four
237	unique datasets (TCGA-BRCA tumor, TCGA-BRCA normal tissue, METABRIC, and GTEx
238	breast tissue) were available to us. We calculated the transcriptional age of all samples using
239	single sample gene set enrichment analysis (ssGSEA) enrichment of genes upregulated with
240	aging in primary human fibroblasts (mSigDB M8910). We found that younger breast cancer
241	patients have an older tumor phenotype compared to chronologically older patients in the

Pan-cancer analysis reveals unique molecular patterns associated with age

TCGA-BRCA and METABRIC datasets (p < 0.05, Fig. 3F). In contrast, healthy breast tissue
samples obtained from GTEx and TCGA do not display a transcriptional age acceleration
phenotype.

245 In order to assess these changes in other tumor types, we used differential pathway 246 enrichment signals from an ssGSEA-based analysis. To do so, we estimated ssGSEA enrichment 247 scores for younger and older patients across tumor types independently and subsequently 248 calculated differential enrichment signals using a t-test. Similar to immune pathway activation 249 (Fig. 2A), we found that pathways associated with aging and senescence show tumor-type 250 specific patterns (Fig. 3G). Interestingly, younger BRCA patients were associated with almost 251 all senescence and aging pathways we could find in MSigDB. Additionally, younger THCA 252 patients were associated with cellular senescence, senescence associated secretory phenotype, 253 oncogene-induced, oxidative stress-induced, and telomere stress-induced senescence along with 254 several aging-related pathways (FDR < 0.05). Similarly, younger OV patients had a greater 255 enrichment score for stress induced premature senescence than old ones (FDR < 0.05). In 256 contrast, LGG was the only tumor type in which these pathways were differentially associated 257 with older patients.

Taken together, we show that molecular age acceleration and senescence are associated with younger patients, rather than older. Since some senescent phenotypes have been shown to promote tumor growth (Fane and Weeraratna, 2020), we show that aggressive tumor phenotypes may be explained, in part, by defunct cellular pathways controlling senescence.

262

263 Age-associated mutational profiles

Pan-cancer analysis reveals unique molecular patterns associated with age

264	The majority of human cancers are caused by the sequential alteration of several genes
265	over the course of multiple years(Vogelstein et al., 2013). We compared somatic mutations
266	between tumors from younger and older patients in order to understand age-associated
267	mutational patterns. The most commonly mutated genes in cancers with age-dependent outcomes
268	were TP53 (39%), PIK3CA (23%), APC (13%), and PTEN (13%) (Fig. 4A). While all variants in
269	a cancer driver genes do not have an equal impact in tumorigenesis, there is an increased
270	probability of tumor growth when driver genes carry a larger number of variants(Carter et al.,
271	2009; Torkamani and Schork, 2008). Interestingly, younger patients were enriched for mutations
272	in driver genes (TP53, ATRX, KMT2C, ARID1A) with more than one variant (FDR < 0.05,
273	Fisher's Exact Test). In line with previous research(Chalmers et al., 2017), we found that older
274	patients had a higher tumor mutation burden (TMB) in most age-associated cancers (FDR < 0.05 ,
275	Fig. 4B).

276 Since mutations in multiple driver genes are associated with aggressive clinical features, 277 we hypothesized that tumors from young patients might be enriched for driver mutations, 278 contributing to their aggressive phenotype. In order to test this hypothesis, we stratified tumor type-specific driver mutations (Bailey et al., 2018) by age groups. We found that tumor-type 279 280 specific nonsynonymous driver gene mutations, with the exception of EGFR in LGG, are more 281 common in younger patients from the UCEC and LGG TCGA cohorts (FDR < 0.005, Fig. 4C), suggesting once more that younger patients, despite their better outcome, have intrinsically more 282 283 aggressive tumors, at least in some tumor types. Younger LGG patients were highly enriched for 284 mutations in TP53, ATRX, and IDH1, and younger UCEC patients were enriched for PTEN, 285 ATRX, CTCF, BRCA2, RPL5, and FAT1 in addition to other genes (Supplementary Table 6). 286 Similarly, younger breast cancer patients in the METABRIC dataset were enriched for TP53

	T un cancer analysis reveals anique morecular patterns associated with age
287	mutations, while older patients were enriched for PIK3CA mutations (Supplemental Fig. 3A).
288	However, we could not detect these associations in the TCGA-BRCA dataset. Additionally,
289	younger UCEC patients were enriched for mutations in DNA damage response genes, suggesting
290	homologous recombination defects (Supplemental Fig. 3B). Furthermore, we report that older
291	UCEC patients are enriched for the high copy number phenotype from integrative genomic
292	clusters published by Getz et al., 2013 (FDR < 0.0001 , Fig. 4D).
293	Next, we stratified UCEC variants by type to better understand functional alterations in
294	younger patients. We found that younger UCEC patients were enriched for frameshift insertions,
295	nonsense, nonstop, splice site, and translation start site mutations (FDR < 0.05 , Fig. 4E).
296	Interestingly, younger patients were enriched for mutations in the PI3K-PTEN-AKT-mTOR and
297	RTK-RAS signaling pathways, while older patients had more $TP53$ mutations (FDR < 0.05, Fig.
298	4F). Enrichment analysis of driver genes more frequently mutated in younger patients revealed
299	four distinct network clusters. These include PIK3CA/RTK-RAS signaling pathways, the beta
300	catenin pathway, DNA-damage response (DDR) pathways, and histone modulatory pathways
301	(FDR < 0.01, Fig. 4G, Supplementary Fig. 3C-F, Supplementary Table 7). Similar enrichment
302	analysis in old UCEC patients revealed a single cluster of $TP53$ associated pathways (FDR <
303	0.05, Supplemental Fig. 3G, Supplementary Table 8), suggesting that tumors from young
304	UCEC patients may have a more heterogeneous mutational landscape.
305	Taken together, we show the enrichment of genomic aberrations in young patients that
306	results in more aggressive tumors. We find that younger UCEC patients are enriched for
307	mutations, while older patients exhibit a high copy number phenotype. Similarly, younger BRCA
308	patients were associated with TP53 mutations, while older ones were associated with PIK3CA
309	mutations.

Pan-cancer analysis reveals unique molecular patterns associated with age

310 **Discussion**

Aging is a major risk factor for global morbidity and mortality, particularly for cancer 311 312 development. While cancers are predominantly diagnosed in older populations aged > 65 years, 313 the increasing frequency of certain tumors in young adults demands immediate attention. With this focus, developing an understanding of aging-related changes in tumors may aid in refining 314 315 various prevention and treatment options. Recent findings have highlighted the links between 316 aging and tumor biology in specific tumor types(Kim et al., 2020; Osako et al., 2020), however, 317 none have yet performed a multi-omics comparison across tumor types. Here, we performed a 318 systematic analysis of publicly available TCGA Cohorts to elucidate the complex and unique 319 biology of tumors across younger and older age groups. We identified six TCGA tumor types 320 that exhibit an age-associated outcome and molecular phenotype. While the aging-associated 321 effects vary by tumor type, we show that these tumor types exhibit dysregulated molecular aging, 322 which drives several processes involving tumorigenesis and the anti-tumor response. We find 323 that most young patients exhibit accelerated epigenetic aging when compared to healthy 324 counterparts, potentially resulting in impaired cellular function. In addition, we find that younger 325 cancer patients often have a stronger association with aging and senescence-related pathways 326 than older ones.

Further, the survey of downstream biological pathways enriched in tumors as a function of age enables us to uncover potential therapeutic opportunities for younger patients compared to older patients, respectively. The interplay of cellular aging and tumor development in younger patients has complex biology involving genomic and epigenomic defects that govern the interaction of tumor cells with the stroma(Schosserer et al., 2017). Indeed, stabilizing the epigenomic landscape through the use of DNA methyltransferase inhibitors (DNMTi) and

histone depositulese inhibitons (UDACi) serve os neuverful enti turner teals coness turner traes
histone deacetylase inhibitors (HDACi) serve as powerful anti-tumor tools across tumor types
(Christmas et al., 2018; Hull et al., 2016; Rodríguez-Paredes and Esteller, 2011). DNMT and
HDAC1/3 inhibition have been shown to be a viable therapeutic strategy for several cancers by
inhibiting tumor growth as well as augmenting the anti-tumor immune response. While clinical
studies have not assessed differential sensitivity in young and old age groups, our analyses
suggest that young patients could exhibit enhanced sensitivity to such treatment regimens.
Recent work by Oltra et al. shows that HDAC5 inhibition differentially induces apoptosis in
breast cancer cell lines sourced from young patients(Oltra et al., 2020). Epigenomic
reprogramming of young breast cancer patients results in age-acceleration at the transcriptional
level as well, thereby causing gross functional alterations. We also find that young breast cancer
patients are enriched for senescence-associated pathways and that these changes are
epigenetically driven. Additionally, we report that young thyroid and endometrial cancer patients
are associated with senescence-related pathways at a transcriptional level.
We show that the senescence-associated pathways enriched in younger breast and thyroid
cancer patients include SASP, an IL-6 mediated secretory phenotype of persistent senescence
involving NF-kB signaling, proteolytic enzymes, growth factors, cytokines, and inflammation,
ultimately causing tumor progression, malignant transformation, and proliferation(Di et al.,
2014; Gosselin et al., 2009; Krtolica et al., 2001; Malaquin et al., 2013; Mavrogonatou et al.,
2020). Additionally, we find that younger breast cancer patients are enriched for oxidative stress-
induced senescence, which promotes senescence in SASP fibroblasts, larger tumors, and
ultimately SASP(Hiebert et al., 2018). As co-administration of senolytic agents with traditional
utilitately SASI (Theoeff et al., 2018). As co-administration of schorytic agents with traditional

Pan-cancer analysis reveals unique molecular patterns associated with age

suggest that tumors from younger patients may be more susceptible to this treatment strategythan older ones.

357 In addition to a senescent phenotype, we show that younger breast cancer patients are 358 enriched for immune-associated pathways. However, tumors from younger breast cancer patients 359 are often triple negative and are associated with BRCA1 and BRCA2 mutations, resulting in 360 aggressive tumors with poor prognosis(Anders et al., 2009; Young et al., 2009) and an increased 361 tumor mutational burden (TMB)(Lal et al., 2019). Several studies have shown a strong link 362 between TMB and the anti-tumor immune response, potentially due to an increased neoantigen 363 burden(Fernandez et al., 2019; Rizvi et al., 2015; Yarchoan et al., 2017). Given the extensive 364 epigenomic aberrations seen in young patients, it is possible that these neoantigens may be 365 epigenetically silenced. This, in turn, would lead to poor prognosis even though the patients are 366 enriched for immune pathways, potentially explaining the increased sensitivity of epigenetic drugs in younger patients(Bell et al., 2018). While the datasets used for this analysis did not have 367 a substantial amount of triple negative cases, future population-based studies could test this 368 369 hypothesis.

370 Next, we find that younger endometrial cancer patients are particularly enriched for 371 mutations in several driver genes, including DNA damage response (DDR) genes. Although 372 pathway enrichment analysis of these genes reveals that the PI3K and RTK-RAS pathways are 373 the most mutated, clinical trials targeting these pathways have shown modest success(Dedes et 374 al., 2011; Oda et al., 2005). Mutations in DDR genes of young UCEC patients lead to 375 homologous recombination deficiencies and hypermutator phenotypes. Such populations are 376 sensitive to several therapeutic strategies, including Poly (ADP-Ribose) polymerase 1 inhibition 377 (PARPi)(McCabe et al., 2006). PTEN was the most differentially mutated gene in young UCEC

378	patients. PARPi, when coupled with PTEN mutations, confers synthetic lethality to such
379	tumors(Mendes-Pereira et al., 2009), suggesting an additional benefit of PARPi in young UCEC
380	patients. Additionally, we show that young LGG patients are enriched for ATRX and IDH1
381	mutations. Similar to PTEN in UCEC, mutations in ATRX confer sensitivity to combined PARPi
382	and radiotherapy(Fazal Salom et al., 2018). Furthermore, young LGG patients may be sensitive
383	to IDH1 inhibitors such as Ivosidenib(DiNardo et al., 2018).
384	Finally, even though young patients are associated with better survival outcomes,
385	molecular data suggests they are more aggressive tumors that may be restrained by a stronger,
386	more highly activated functional immune system. We found that the gene signatures of immune
387	pathways exhibit higher expression in younger donors, with increased infiltration of B and T
388	cells (the primary cell types associated with anti-tumor immune memory). Therefore, we have
389	begun to characterize the unique biology of tumors in young adults, demonstrate that aging-
390	associated dysfunction is tumor-type specific, and explore the biological systems underlying
391	aggressive tumors. These dysregulated aging and oncogenic processes associated with the
392	aggressive tumors from young patients may be leveraged for differential therapeutic strategies
393	and biomarker discovery.

Pan-cancer analysis reveals unique molecular patterns associated with age

394 Methods

395 Age Groups

- 396 Previously identified quartiles served as age group limits for individual age-associated tumor
- 397 types from the TCGA cohort. Additionally, the quartile limits for the TCGA breast cancer cohort
- 398 was employed to stratify the METABRIC cohort into age groups. The GTEx cohort was,
- 399 however, classified as young and old using an alternate methodology. Young samples are from
- 400 individuals younger than 50 years, and old samples are from individuals older than 59 years.
- 401 This was necessary since age was a discrete variable in the GTEx dataset.

402 Differential Gene Expression Analysis

403 Differentially expressed genes (FDR < 0.05) between young and old age groups were identified

404 across all datasets. In the case of the microarray dataset, *limma* was run with default parameters.

- 405 For RNA-Seq based data, lowly expressed genes that had less than two counts per million reads
- 406 in more than two samples were removed from the analysis. The data was voom transformed prior
- 407 to fitting a linear model using *limma*(Ritchie et al., 2015). Empirical Bayes shrinkage was
- 408 applied to the model in both cases.

409 Pathway Enrichment Analysis

410 We computed pathway enrichment analysis using GSEA and Reactome pathway analysis.

- 411 Briefly, GSEA was computed for differential gene expression results using 1000 permutations of
- 412 hallmark and KEGG pathways using the *fgsea* R package(Sergushichev, 2016). We carried out
- 413 Reactome pathway enrichment analysis using *clusterProfiler*(Yu et al., 2012). Pathways with an
- 414 adjusted p-value (Benjamini-Hochberg) less than 0.05 were considered significantly enriched.

415 Differential Methylation Analysis

Pan-cancer analysis reveals unique molecular patterns associated with age

- 416 We transformed gene level beta values to m-values using the *wateRmelon* R package(Pidsley et
- 417 al., 2013) and subsequently identified differentially methylated genes using *limma*.

418 ssGSEA Analysis

- 419 ssGSEA was estimated using publicly available signatures on MSigDB and the GSVA R
- 420 package(Hänzelmann et al., 2013). The Poisson kernel was employed for microarray and raw
- 421 count data, while the Gaussian kernel was employed with TPM data. Differential analyses were
- 422 conducted using the Wilcoxon test and t test.

423 DNAm Age Calculation

- 424 The epigenetic age for age-dependent cancers, along with normal adjacent tissue (NAT), was
- 425 imputed using the online DNAm age calculator (<u>https://dnamage.genetics.ucla.edu/home</u>)

426 (Horvath, 2013). This tool predicts age from the DNAm coefficients of 353 CpG sites.

- 427 Imputations that correlated with the internal gold standard less than 0.8 were discarded, as
- recommended by the tool, from downstream analyses. Groups were compared using Wilcoxon

429 tests.

430 **RNA Age Calculation**

- 431 We used batch corrected FPKM data (TCGA tumor, TCGA NAT and GTEx) obtained from
- 432 Wang et al. (Wang et al., 2018) to determine transcriptional age using the *RNAAgeCalc* R
- 433 package(Ren and Kuan, 2020). The regression model for imputing age was the *Dev* signature,
- 434 which encompassed coefficients for genes that had the largest variation across samples. Groups
- 435 were compared using Wilcoxon tests.

436 Gene Overlap

437 Pairwise comparison of differentially expressed genes (FDR < 0.05) between young and old

438 samples from each tumor type was performed using Fisher's exact tests from the *GeneOverlap* R

Pan-cancer analysis reveals unique molecular patterns associated with age

- 439 package. P-values were corrected by the Benjamini-Hochberg method. The overlap between
- 440 hypermethylated (FDR < 0.05) and downregulated genes (FDR < 0.05), and vice versa, was
- 441 similarly computed.

442 Differential mutation analysis

443 MAF files were obtained from GDC and METABRIC, respectively. We discarded the top 20

444 frequently mutated genes (FLAGS) in public exomes before proceeding with analyses (Shyr et

- al., 2014). The enrichment of Single Nucleotide Variants (SNVs) in age groups per tumor type
- 446 was calculated using Fisher's exact test from the *maftools* R package(Mayakonda et al., 2018).
- 447 Tumor mutation burden (TMB) was calculated by dividing the total number of nonsynonymous
- 448 variants in a sample by genome size (50 MB). SNV classes and TMB were compared across age
- 449 groups using the Wilcoxon test.

450 Data Availability

- 451 TCGA clinical data were obtained from Liu et al., 2018), CIBERSORT data from
- 452 Vesteinn et al. (Thorsson et al., 2018), driver gene calls from Bailey et al. (Bailey et al., 2018)
- 453 and TCGA-UCEC integrative genomic clusters from Getz et al. (Getz et al., 2013). Gene
- 454 expression data for TCGA samples using RNASeq, methylation profiling data using Illumina
- 455 450K, and mutect2 MAF files were downloaded from the Genomic Data Commons.
- 456 Preprocessed gene-level methylation data were obtained from GDAC. Batch corrected gene
- 457 expression data were obtained from Wang et al. (Wan g et al., 2018). Clinical data, gene
- 458 expression by microarray, and MAF files for the Metabric dataset(Curtis et al., 2012; Pereira et
- 459 al., 2016) were obtained from cbioportal(Gao et al., 2013). Gene expression using RNASeq was
- 460 obtained from the GTEx consortium v8 release.
- 461 Code Availability

- 462 All analyses were performed on R (<u>www.r-project.org</u>) version 3.5.1. Code for all analyses is
- 463 available on <u>https://github.com/yajass/tcga_aging_final</u>.

Pan-cancer analysis reveals unique molecular patterns associated with age

464 Figure Legends

465 Figure 1: Tumor type selection

- 466 (A) Hazard ratios (HRs) for overall survival as a function of tumor diagnosis age. HRs greater
- than 1 are associated with decreased survival probability in older patients. Tumor types in dark
- 468 blue have significantly different outcomes based on age (FDR < 0.01) (B) Differentially
- 469 expressed genes (DEG) between younger and older patients (FDR < 0.05) from tumor types with
- 470 HR > 1. The bar plot indicates the fraction of DEG. Tumor types with HR > 1 and DEG > 1%
- 471 were termed age-associated cancers (light blue).

472 Figure 2: Differential gene expression and methylation links immune function and

473 senescence to young patients

474 (A) Gene set enrichment analysis of DEG between younger and older patients across tumor

475 types. Pathways in red are associated with older patients, and those in blue are associated with

476 younger patients (FDR < 0.05). (B) Gene set enrichment analysis of DEG between tissue sourced

477 from younger and older cancer patients (black) as well as corresponding healthy individuals

478 (grey). (C) Pearson correlation coefficients of CIBERSORT (relative) scores with age across

479 tumor types (FDR < 0.05). (D) The bar plots show the overlap between hypomethylated and

480 over-expressed genes in young (top) and old patients (bottom). (E) Reactome pathway

481 enrichment analysis of hypomethylated and over-expressed genes. Point size reflects the ratio of

the number of genes present in the differential gene list and the number of genes present in the

483 pathway.

484 Figure 3: Young patients are associated with senescence and accelerated aging

(A) Scatterplot of DNA methylation age and chronological age in tumor (dark blue) and healthy

486 (red) tissue. (B) The difference between DNA methylation age and chronological age (DNAm

Pan-cancer analysis reveals unique molecular patterns associated with age

487	age acceleration difference) is plotted against chronological age bins. (C) DNAm age
488	acceleration difference is plotted against age bins for breast cancer (dark green), colon cancer
489	(light brown), low grade glioma (blue), thyroid cancer (dark brown), and uterine endometrial
490	carcinoma (green). (D) The difference between RNA age and chronological age (RNA age
491	acceleration difference) is plotted against age bins for tumor (dark blue) and normal (red)
492	samples. (E) Paired analysis of RNA age acceleration difference in younger and older patients.
493	(F) Single sample gene set enrichment analysis of genes associated with aging in healthy (top)
494	and tumor (bottom) breast samples. (G) The scatter plot shows BH-adjusted p values for
495	differential pathway enrichment analysis between young (filled circles) and old (hollow circles)
496	patients from the BRCA (dark green), COAD (light brown), LGG (blue), OV (dark brown),
497	THCA (green) and UCEC (purple) TCGA cohorts.

498 Figure 4: Mutation Analysis

499 (A) Oncoplot of the top 10 most frequently mutated genes in BRCA, COAD, LGG, OV, THCA, 500 and UCEC. (B) Comparison of tumor mutation burden in younger (blue) and older (yellow) 501 patients. Stars indicate BH-adjusted p values. (C) The forest plot shows tumor-type specific 502 driver gene mutations more commonly found in younger (blue) and older patients (FDR < 503 0.005). (D) Stacked bar plots show the relative proportion of integrative genomic clusters in 504 younger and older UCEC patients. (E) Boxplots show the frequency of variants in younger (blue) 505 and older (yellow) UCEC patients. Stars indicate BH-adjusted p values. (F) Oncoplot shows 506 mutations that are differentially enriched in younger and older UCEC patients (FDR <0.05) and 507 is accompanied by a lollipop plot of PTEN. (G) Reactome pathway analysis of driver genes 508 mutated in young UCEC patients. Nodes represent the fraction of the number of mutated genes 509 associated with young UCEC patients (FDR < 0.05) and pathway size. Edges represent the

Pan-cancer analysis reveals unique molecular patterns associated with age

510 number of shared genes across pathways.

511

512 Figure S1:

513 (A) Age distribution that classifies patients as younger and older. (B) The forest plot shows the 514 association between tumor stage and age. Tumor stages with a log odds ratio greater than 0 are 515 associated with older patients. (C) Gene expression correlation coefficients (Spearman) with age 516 for genes associated with tumor progression markers are visualized as a heatmap. Stars indicate 517 BH-adjusted p values. (D) Gene set enrichment analysis of DEG for KEGG pathways associated 518 with tumor proliferation. Pathways in red are associated with older patients, and those in blue are 519 associated with younger patients (FDR < 0.05). (E) The overlap between DEGs associated with 520 young (blue) and old (red) patients visualized as a heatmap. The color gradient reflects log odds 521 ratios, and stars indicate BH-adjusted p values. (F) The Venn diagrams show the overlap 522 between DEGs (FDR < 0.05) associated with young and old individuals across tumor (TCGA) 523 and healthy (GTEx) datasets. (G) The total number of differentially methylated genes (DMG) in 524 younger and older patients are visualized (top). Stacked bar plots represent relative amounts of 525 hypermethylation status in younger (blue) and older (yellow) patients. 526 Figure S2: Scatter plots of imputed RNA age and chronological age for TCGA and GTEx

- 527 datasets
- 528 **Figure S3**:

529 (A) Oncoplot of differential mutations in younger and older patients from the METABRIC

530 dataset (FDR < 0.05) along with a lollipop plot showing the type of P53 variants. (B) The

beatmap displays mutation status in DNA damage response genes. Black areas represent mutated

532 genes. (C-F) Oncoplots of the RTK-RAS and PI3K pathways for younger and older patients.

- 533 Genes in blue are oncogenes, while genes in red are tumor suppressor genes. (G) The network
- 534 diagram represents reactome pathway enrichment analysis of driver genes in older UCEC
- patients. Nodes represent the fraction of the number of mutated genes associated with old UCEC
- patients (FDR < 0.05) and pathway size. Edges represent the number of shared genes across
- 537 pathways.

Pan-cancer analysis reveals unique molecular patterns associated with age

538 **References**

- 539 Abe, S., Takeda, H., Nishio, S. ya, and Usami, S. ichi (2018). Sensorineural hearing loss and
- 540 mild cardiac phenotype caused by an EYA4 mutation. Hum. Genome Var. 5, 1–4.
- 541 Ahnen, D.J., Wade, S.W., Jones, W.F., Sifri, R., Silveiras, J.M., Greenamyer, J., Guiffre, S.,
- 542 Axilbund, J., Spiegel, A., and You, Y.N. (2014). The increasing incidence of young-onset
- 543 colorectal cancer: A call to action. Mayo Clin. Proc. 89, 216–224.
- An, W., Yao, S., Sun, X., Hou, Z., Lin, Y., Su, L., and Liu, X. (2019). Glucocorticoid
- 545 modulatory element-binding protein 1 (GMEB1) interacts with the de-ubiquitinase USP40 to
- 546 stabilize CFLAR L and inhibit apoptosis in human non-small cell lung cancer cells. J. Exp. Clin.
- 547 Cancer Res. *38*, 181.
- 548 Anders, C.K., Johnson, R., Litton, J., Phillips, M., and Bleyer, A. (2009). Breast Cancer Before
- 549 Age 40 Years. Semin. Oncol. *36*, 237–249.
- 550 Bailey, M.H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A.,
- 551 Colaprico, A., Wendl, M.C., Kim, J., Reardon, B., et al. (2018). Comprehensive Characterization
- of Cancer Driver Genes and Mutations. Cell 173, 371-385.e18.
- 553 Begik, O., Lucas, M.C., Liu, H., Ramirez, J.M., Mattick, J.S., and Novoa, E.M. (2020).
- 554 Integrative analyses of the RNA modification machinery reveal tissue- And cancer-specific
- signatures. Genome Biol. 21, 1–24.
- 556 Behnia, R., Panic, B., Whyte, J.R.C., and Munro, S. (2004). Targeting of the Arf-like GTPase
- 557 Arl3p to the Golgi requires N-terminal acetylation and the membrane protein Sys1p. Nat. Cell
- 558 Biol. *6*, 405–413.
- 559 Bell, J.A., Galaznik, A., Huelin, R., Stokes, M., Guo, Y., Fram, R.J., and Faller, D. V. (2018).
- 560 Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With

- 561 Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Clin.
- 562 Lymphoma, Myeloma Leuk. 18, e157–e166.
- 563 Ben-Aharon, I., Elkabets, M., Pelossof, R., Yu, K.H., Iacubuzio-Donahue, C.A., Leach, S.D.,
- Lowery, M.A., Goodman, K.A., and O'Reilly, E.M. (2019). Genomic landscape of pancreatic
- adenocarcinoma in younger versus older patients: Does age matter? Clin. Cancer Res. 25, 2185–
- 566 2193.
- 567 Bleyer, A., Barr, R., Hayes-Lattin, B., Thomas, D., Ellis, C., and Anderson, B. (2008). The
- 568 distinctive biology of cancer in adolescents and young adults. Nat. Rev. Cancer 8, 288–298.
- 569 Cannon, T.D., Hennah, W., Van Erp, T.G.M., Thompson, P.M., Lonnqvist, J., Huttunen, M.,
- 570 Gasperoni, T., Tuulio-Henriksson, A., Pirkola, T., Toga, A.W., et al. (2005). Association of
- 571 DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired
- short- and long-term memory. Arch. Gen. Psychiatry 62, 1205–1213.
- 573 Carter, H., Chen, S., Isik, L., Tyekucheva, S., Velculescu, V.E., Kinzler, K.W., Vogelstein, B.,
- and Karchin, R. (2009). Cancer-specific high-throughput annotation of somatic mutations:
- 575 Computational prediction of driver missense mutations. Cancer Res. 69, 6660–6667.
- 576 Chalmers, Z.R., Connelly, C.F., Fabrizio, D., Gay, L., Ali, S.M., Ennis, R., Schrock, A.,
- 577 Campbell, B., Shlien, A., Chmielecki, J., et al. (2017). Analysis of 100,000 human cancer
- 578 genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34.
- 579 Christmas, B.J., Rafie, C.I., Hopkins, A.C., Scott, B.A., Ma, H.S., Cruz, K.A., Woolman, S.,
- 580 Armstrong, T.D., Connolly, R.M., Azad, N.A., et al. (2018). Entinostat converts immune-
- 581 resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming
- tumor-infiltrating MDSCs. Cancer Immunol. Res. 6, 1561–1577.
- 583 Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch,

- A.G., Samarajiwa, S., Yuan, Y., et al. (2012). The genomic and transcriptomic architecture of
- 585 2,000 breast tumours reveals novel subgroups. Nature *486*, 346–352.
- 586 Dedes, K.J., Wetterskog, D., Ashworth, A., Kaye, S.B., and Reis-Filho, J.S. (2011). Emerging
- therapeutic targets in endometrial cancer. Nat. Rev. Clin. Oncol. 8, 261–271.
- 588 Di, G.H., Liu, Y., Lu, Y., Liu, J., Wu, C., and Duan, H.F. (2014). IL-6 secreted from senescent
- 589 mesenchymal stem cells promotes proliferation and migration of breast cancer cells. PLoS One
- 590 *9*.
- 591 DiNardo, C.D., Stein, E.M., de Botton, S., Roboz, G.J., Altman, J.K., Mims, A.S., Swords, R.,
- 592 Collins, R.H., Mannis, G.N., Pollyea, D.A., et al. (2018). Durable Remissions with Ivosidenib in
- 593 *IDH1* -Mutated Relapsed or Refractory AML. N. Engl. J. Med. 378, 2386–2398.
- 594 Fane, M., and Weeraratna, A.T. (2020). How the ageing microenvironment influences tumour
- 595 progression. Nat. Rev. Cancer 20, 89–106.
- 596 Fazal Salom, J., Bjerke, L., Carvalho, D., Boult, J., Mackay, A., Pemberton, H., Molinari, V.,
- 597 Clarke, M., Vinci, M., Carceller, F., et al. (2018). PDTM-33. ATRX LOSS CONFERS
- 598 ENHANCED SENSITIVITY TO COMBINED PARP INHIBITION AND RADIOTHERAPY
- 599 IN PAEDIATRIC GLIOBLASTOMA MODELS. Neuro. Oncol. 20, vi210–vi211.
- 600 Fernandez, E.M., Eng, K., Beg, S., Beltran, H., Faltas, B.M., Mosquera, J.M., Nanus, D.M.,
- 601 Pisapia, D.J., Rao, R.A., Robinson, B.D., et al. (2019). Cancer-Specific Thresholds Adjust for
- 602 Whole Exome Sequencing–Based Tumor Mutational Burden Distribution. JCO Precis. Oncol. 3,
- 603 1–12.
- 604 Fleury, H., Malaquin, N., Tu, V., Gilbert, S., Martinez, A., Olivier, M.A., Sauriol, A.,
- 605 Communal, L., Leclerc-Desaulniers, K., Carmona, E., et al. (2019). Exploiting interconnected
- synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat.

- 607 Commun. 10, 1–15.
- 608 Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., and Santoro, A. (2018). Inflammaging: a
- new immune-metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 14, 576–590.
- 610 Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A.,
- 611 Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex cancer genomics and clinical
- 612 profiles using the cBioPortal. Sci. Signal. 6, pl1.
- 613 Garaud, S., Buisseret, L., Solinas, C., Gu-Trantien, C., De Wind, A., Van Den Eynden, G.,
- 614 Naveaux, C., Lodewyckx, J.N., Boisson, A., Duvillier, H., et al. (2019). Tumor-infiltrating B
- 615 cells signal functional humoral immune responses in breast cancer. JCI Insight 4.
- 616 Gayle, S.S., Sahni, J.M., Webb, B.M., Weber-Bonk, K.L., Shively, M.S., Spina, R., Bar, E.E.,
- 617 Summers, M.K., and Keri, R.A. (2019). Targeting BCL-xL improves the efficacy of
- 618 bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting
- 619 the death of senescent cells. J. Biol. Chem. 294, 875–886.
- 620 Getz, G., Gabriel, S.B., Cibulskis, K., Lander, E., Sivachenko, A., Sougnez, C., Lawrence, M.,
- 621 Kandoth, C., Dooling, D., Fulton, R., et al. (2013). Integrated genomic characterization of
- 622 endometrial carcinoma. Nature 497, 67–73.
- 623 Gimeno-Valiente, F., Riffo-Campos, Á.L., Vallet-Sánchez, A., Siscar-Lewin, S., Gambardella,
- 624 V., Tarazona, N., Cervantes, A., Franco, L., Castillo, J., and López-Rodas, G. (2019). ZNF518B
- 625 gene up-regulation promotes dissemination of tumour cells and is governed by epigenetic
- 626 mechanisms in colorectal cancer. Sci. Rep. 9, 1–12.
- 627 Gosselin, K., Martien, S., Pourtier, A., Vercamer, C., Ostoich, P., Morat, L., Sabatier, L.,
- 628 Duprez, L., De Roodenbeke, C.T.K., Gilson, E., et al. (2009). Senescence-associated oxidative
- DNA damage promotes the generation of neoplastic cells. Cancer Res. 69, 7917–7925.

- 630 Hänzelmann, S., Castelo, R., and Guinney, J. (2013). GSVA: Gene set variation analysis for
- 631 microarray and RNA-Seq data. BMC Bioinformatics 14, 7.
- 632 Hiebert, P., Wietecha, M.S., Cangkrama, M., Haertel, E., Mavrogonatou, E., Stumpe, M.,
- 633 Steenbock, H., Grossi, S., Beer, H.D., Angel, P., et al. (2018). Nrf2-Mediated Fibroblast
- 634 Reprogramming Drives Cellular Senescence by Targeting the Matrisome. Dev. Cell 46, 145-
- 635 161.e10.
- 636 Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez,
- 637 R., Robert, C., Schadendorf, D., Hassel, J.C., et al. (2010). Improved survival with ipilimumab in
- 638 patients with metastatic melanoma. N. Engl. J. Med. *363*, 711–723.
- Horvath, S. (2013). DNA methylation age of human tissues and cell types. Genome Biol. 14,D115
- 640 R115.
- 641 Hull, E.E., Montgomery, M.R., and Leyva, K.J. (2016). HDAC Inhibitors as Epigenetic
- 642 Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases.
- 643 Biomed Res. Int. 2016.
- Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer Statistics, 2010. CA. Cancer J. Clin.
 60, 277–300.
- Jonassen, T., and Clarke, C.F. (2000). Isolation and functional expression of human COQ3, a
- 647 gene encoding a methyltransferase required for ubiquinone biosynthesis. J. Biol. Chem. 275,
- **648** 12381–12387.
- 649 Kavela, S., Shinde, S.R., Ratheesh, R., Viswakalyan, K., Bashyam, M.D., Gowrishankar, S.,
- 650 Vamsy, M., Pattnaik, S., Rao, S., Sastry, R.A., et al. (2013). PNUTS functions as a proto-
- oncogene by sequestering PTEN. Cancer Res. 73, 205–214.
- 652 Keegan, T.H.M., Ries, L.A.G., Barr, R.D., Geiger, A.M., Dahlke, D.V., Pollock, B.H., and

Pan-cancer analysis reveals unique molecular patterns associated with age

- Bleyer, W.A. (2016). Comparison of cancer survival trends in the United States of adolescents
- and young adults with those in children and older adults. Cancer 122, 1009–1016.
- 655 Kim, Y.-J., Kim, K., Lee, K.H., Kim, J., and Jung, W. (2020). Immune expression signatures as
- 656 candidate prognostic biomarkers of age and gender survival differences in cutaneous melanoma.
- 657 Sci. Rep. 10, 12322.
- 658 Kolanczyk, M., Pech, M., Zemojtel, T., Yamamoto, H., Mikula, I., Calvaruso, M.A., Van Den
- Brand, M., Richter, R., Fischer, B., Ritz, A., et al. (2011). NOA1 is an essential GTPase required
- 660 for mitochondrial protein synthesis. Mol. Biol. Cell 22, 1–11.
- 661 Krtolica, A., Parrinello, S., Lockett, S., Desprez, P.Y., and Campisi, J. (2001). Senescent
- fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging.
- 663 Proc. Natl. Acad. Sci. U. S. A. 98, 12072–12077.
- Lal, A., Ramazzotti, D., Weng, Z., Liu, K., Ford, J.M., and Sidow, A. (2019). Comprehensive
- 665 genomic characterization of breast tumors with BRCA1 and BRCA2 mutations. BMC Med.

666 Genomics 12, 84.

- 667 Lalloo, F., Varley, J., Moran, A., Ellis, D., O'Dair, L., Pharoah, P., Antoniou, A., Hartley, R.,
- 668 Shenton, A., Seal, S., et al. (2006). BRCA1, BRCA2 and TP53 mutations in very early-onset
- breast cancer with associated risks to relatives. Eur. J. Cancer 42, 1143–1150.
- 670 Laurberg, J.R., Jensen, J.B., Schepeler, T., Borre, M., Ørntoft, T.F., and Dyrskjøt, L. (2014).
- 671 High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients
- 672 with advanced bladder cancer. BMC Cancer 14.
- 673 Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D.,
- 674 Luber, B.S., Azad, N.S., Laheru, D., et al. (2015). PD-1 Blockade in Tumors with Mismatch-
- 675 Repair Deficiency. N. Engl. J. Med. 372, 2509–2520.

- 676 Lee, J.Y., Kim, J.M., Jeong, D.S., and Kim, M.H. (2018). Transcriptional activation of EGFR by
- HOXB5 and its role in breast cancer cell invasion. Biochem. Biophys. Res. Commun. 503,
- **678** 2924–2930.
- 679 Liu, C.C., Cai, D.L., Sun, F., Wu, Z.H., Yue, B., Zhao, S.L., Wu, X.S., Zhang, M., Zhu, X.W.,
- 680 Peng, Z.H., et al. (2017). FERMT1 mediates epithelial-mesenchymal transition to promote colon
- 681 cancer metastasis via modulation of β -catenin transcriptional activity. Oncogene 36, 1779–1792.
- 682 Liu, J., Lichtenberg, T., Hoadley, K.A., Poisson, L.M., Lazar, A.J., Cherniack, A.D., Kovatich,
- 683 A.J., Benz, C.C., Levine, D.A., Lee, A. V., et al. (2018). An Integrated TCGA Pan-Cancer
- 684 Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell 173, 400-
- 685 416.e11.
- 686 Malaquin, N., Vercamer, C., Bouali, F., Martien, S., Deruy, E., Wernert, N., Chwastyniak, M.,
- 687 Pinet, F., Abbadie, C., and Pourtier, A. (2013). Senescent Fibroblasts Enhance Early Skin
- 688 Carcinogenic Events via a Paracrine MMP-PAR-1 Axis. PLoS One 8, e63607.
- 689 Mavrogonatou, E., Pratsinis, H., and Kletsas, D. (2020). The role of senescence in cancer
- 690 development. Semin. Cancer Biol. 62, 182–191.
- 691 Mayakonda, A., Lin, D.C., Assenov, Y., Plass, C., and Koeffler, H.P. (2018). Maftools: Efficient
- and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747–1756.
- 693 McCabe, N., Turner, N.C., Lord, C.J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S.,
- 694 O'Connor, M.J., Tutt, A.N., Zdzienicka, M.Z., et al. (2006). Deficiency in the repair of DNA
- 695 damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase
- 696 inhibition. Cancer Res. *66*, 8109–8115.
- 697 Mendes-Pereira, A.M., Martin, S.A., Brough, R., McCarthy, A., Taylor, J.R., Kim, J.S.,
- 698 Waldman, T., Lord, C.J., and Ashworth, A. (2009). Synthetic lethal targeting of PTEN mutant

- 699 cells with PARP inhibitors. EMBO Mol. Med. 1, 315–322.
- 700 Montecino-Rodriguez, E., Berent-Maoz, B., and Dorshkind, K. (2013). Causes, consequences,
- and reversal of immune system aging. J. Clin. Invest. 123, 958.
- 702 Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, C.D., Diehn,
- 703 M., and Alizadeh, A.A. (2015). Robust enumeration of cell subsets from tissue expression
- 704 profiles. Nat. Methods *12*, 453–457.
- 705 Nikolich-Žugich, J. (2018). The twilight of immunity: Emerging concepts in aging of the
- immune system review-article. Nat. Immunol. 19, 10–19.
- 707 Oda, K., Stokoe, D., Taketani, Y., and McCormick, F. (2005). High frequency of coexistent
- 708 mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65, 10669-
- 709 10673.
- 710 Oltra, S.S., Peña-Chilet, M., Flower, K., Martinez, M.T., Alonso, E., Burgues, O., Lluch, A.,
- Flanagan, J.M., and Ribas, G. (2019). Acceleration in the DNA methylation age in breast cancer
- tumours from very young women. Sci. Rep. 9, 14991.
- 713 Oltra, S.S., Cejalvo, J.M., Tormo, E., Albanell, M., Ferrer, A., Nacher, M., Bermejo, B.,
- Hernando, C., Chirivella, I., Alonso, E., et al. (2020). HDAC5 Inhibitors as a Potential Treatment
- in Breast Cancer Affecting Very Young Women. Cancers (Basel). 12, 412.
- 716 Osako, T., Lee, H., Turashvili, G., Chiu, D., McKinney, S., Joosten, S.E.P., Wilkinson, D.,
- 717 Nielsen, T.O., Zwart, W., Emerman, J.T., et al. (2020). Age-correlated protein and transcript
- respression in breast cancer and normal breast tissues is dominated by host endocrine effects. Nat.
- 719 Cancer 1, 518–532.
- 720 Pereira, B., Chin, S.F., Rueda, O.M., Vollan, H.K.M., Provenzano, E., Bardwell, H.A., Pugh, M.,
- Jones, L., Russell, R., Sammut, S.J., et al. (2016). The somatic mutation profiles of 2,433 breast


- 722 cancers refines their genomic and transcriptomic landscapes. Nat. Commun. 7, 1–16.
- 723 Pidsley, R., Y Wong, C.C., Volta, M., Lunnon, K., Mill, J., and Schalkwyk, L.C. (2013). A data-
- driven approach to preprocessing Illumina 450K methylation array data. BMC Genomics 14,
- 725 293.
- 726 Pyonteck, S.M., Akkari, L., Schuhmacher, A.J., Bowman, R.L., Sevenich, L., Quail, D.F., Olson,
- 727 O.C., Quick, M.L., Huse, J.T., Teijeiro, V., et al. (2013). CSF-1R inhibition alters macrophage
- 728 polarization and blocks glioma progression. Nat. Med. 19, 1264–1272.
- 729 Ren, X., and Kuan, P.F. (2020). RNAAgeCalc: A multi-tissue transcriptional age calculator.
- 730 BioRxiv 2020.02.14.950188.
- 731 Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015). limma
- 732 powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic
- 733 Acids Res. *43*.
- 734 Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W.,
- 735 Yuan, J., Wong, P., Ho, T.S., et al. (2015). Mutational landscape determines sensitivity to PD-1
- blockade in non-small cell lung cancer. Science (80-.). 348, 124–128.
- 737 Rodríguez-Paredes, M., and Esteller, M. (2011). Cancer epigenetics reaches mainstream
- 738 oncology. Nat. Med. 17, 330–339.
- 739 Schosserer, M., Grillari, J., and Breitenbach, M. (2017). The dual role of cellular senescence in
- 740 developing tumors and their response to cancer therapy. Front. Oncol. 7, 278.
- 741 Sen, P., Shah, P.P., Nativio, R., and Berger, S.L. (2016). Epigenetic Mechanisms of Longevity
- 742 and Aging. Cell *166*, 822–839.
- 743 Sergushichev, A.A. (2016). An algorithm for fast preranked gene set enrichment analysis using
- cumulative statistic calculation. BioRxiv 060012.

- 745 Shyr, C., Tarailo-Graovac, M., Gottlieb, M., Lee, J.J.Y., Van Karnebeek, C., and Wasserman,
- 746 W.W. (2014). FLAGS, frequently mutated genes in public exomes. BMC Med. Genomics 7.
- 747 Siegel, R.L., Miller, K.D., and Jemal, A. (2020). Cancer statistics, 2020. CA. Cancer J. Clin. 70,
- 748 7–30.
- 749 Thorsson, V., Gibbs, D.L., Brown, S.D., Wolf, D., Bortone, D.S., Ou Yang, T.H., Porta-Pardo,
- E., Gao, G.F., Plaisier, C.L., Eddy, J.A., et al. (2018). The Immune Landscape of Cancer.
- 751 Immunity 48, 812-830.e14.
- 752 Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F.,
- 753 Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. (2012). Safety, Activity, and
- 754 Immune Correlates of Anti–PD-1 Antibody in Cancer. N. Engl. J. Med. 366, 2443–2454.
- Torkamani, A., and Schork, N.J. (2008). Prediction of cancer driver mutations in protein kinases.
 Cancer Res. *68*, 1675–1682.
- 757 Tricoli, J. V., Boardman, L.A., Patidar, R., Sindiri, S., Jang, J.S., Walsh, W.D., McGregor, P.M.,
- 758 Camalier, C.E., Mehaffey, M.G., Furman, W.L., et al. (2018). A mutational comparison of adult
- and adolescent and young adult (AYA) colon cancer. Cancer 124, 1070–1082.
- Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., and Kinzler, K.W.
- 761 (2013). Cancer genome landscapes. Science (80-.). *340*, 1546–1558.
- 762 Wang, Q., Armenia, J., Zhang, C., Penson, A. V., Reznik, E., Zhang, L., Minet, T., Ochoa, A.,
- 763 Gross, B.E., Iacobuzio-Donahue, C.A., et al. (2018). Data Descriptor: Unifying cancer and
- normal RNA sequencing data from different sources. Sci. Data 5, 1–8.
- 765 Yarchoan, M., Hopkins, A., and Jaffee, E.M. (2017). Tumor mutational burden and response rate
- to PD-1 inhibition. N. Engl. J. Med. 377, 2500–2501.
- 767 Young, S.R., Pilarski, R.T., Donenberg, T., Shapiro, C., Hammond, L.S., Miller, J., Brooks,


Pan-cancer analysis reveals unique molecular patterns associated with age


- 768 K.A., Cohen, S., Tenenholz, B., DeSai, D., et al. (2009). The prevalence of BRCA1 mutations
- among young women with triple-negative breast cancer. BMC Cancer 9, 86.
- 770 Yu, G., and He, Q.Y. (2016). ReactomePA: An R/Bioconductor package for reactome pathway
- analysis and visualization. Mol. Biosyst. *12*, 477–479.
- Yu, G., Wang, L.G., Han, Y., and He, Q.Y. (2012). ClusterProfiler: An R package for comparing
- biological themes among gene clusters. Omi. A J. Integr. Biol. 16, 284–287.
- 774 Zhang, C., Xin, H., Zhang, W., Yazaki, P.J., Zhang, Z., Le, K., Li, W., Lee, H., Kwak, L.,
- Forman, S., et al. (2016). CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the
- 776 Transcription Factor STAT3 in B Cells to Promote Cancer. Immunity 44, 913–923.


777




















D



Spearman






COAD

BRCA

vco


THCA


Figure S2



Chronological Age







D	2	0.08.30.20184762; this version
)	i,	the author/funder, who has
á	2	vailable under a CC-BY-NC-
	Ĭ	
		(
		► ·· ····· · · · · · · · · · · · · · ·
		1
		<u></u>
		per en
		<u> </u>
		L
		[44] And Charles and Charle
		[25] M. K. K. Terr, T. K.
		Ξ
		_
		in an analysis of the second state of the seco
		Englander og fra skalet af skalet

ger en generation and ser

Canoer

STER OT STATION ADDRESS

E

C-BY-	NC-ND 4.0 Inte	
•		
-		
• •		
<u>:</u> ·		
_	······································	
,	and a second second The second s The second se	
1		

2010-5750 Million

